GeneDx Holdings Corp. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
GeneDx reported Q2 2026 revenue of $114.4M (11% YoY growth), with exome/genome revenue at $100.3M (17% YoY). Test volume grew 32% YoY to 30,785 tests. The company achieved adjusted gross margin of 70% and adjusted net income of $0.4M. On August 3, 2026, GeneDx amended its loan agreement with Blackstone, adding $50M in new term loan capacity (raising total facility to $150M), and Blackstone affiliate purchased ~$5M Class A common stock at $61/share, bringing pro forma cash to ~$188M. Full year 2026 guidance reaffirmed: $475-490M revenue, ≥30% volume growth, ~70% adjusted gross margin, positive adjusted net income.
Why this rating
Debt expansion + equity investment signal confidence but moderate relative to $1.7B market cap. 32% volume growth and margin improvement are strong operationally. Return to adjusted profitability is positive. However, GAAP net loss of $17.7M, Q1 impairment charge, and high OpEx as % of revenue temper trajectory impact.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.